Keros Therapeutics is a biotechnology company dedicated to the discovery and development of therapeutics for hematological and musculoskeletal disorders. Its lead protein therapeutic product candidate, KER-050, is designed to increase red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-β family of proteins to promote hematopoiesis. Keros Therapeutics' small molecule product candidate, KER-047, is designed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva. The company also develops KER-01, a preclinical protein therapeutic product candidate that is designed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.
|HQ||Lexington, MA, US||Map|
Net income (FY, 2020)
EBIT (FY, 2020)
Market capitalization (17-Sept-2021)
Closing stock price (17-Sept-2021)
|Company Name||Date||Deal Size|
|Keros Therapeutics Australia|
When was Keros Therapeutics founded?
Keros Therapeutics was founded in 2015.
Who are Keros Therapeutics key executives?
Keros Therapeutics's key executives are Jasbir Seehra, Jennifer Lachey and Claudia Ordonez.
How many employees does Keros Therapeutics have?
Keros Therapeutics has 23 employees.
Who are Keros Therapeutics competitors?
Competitors of Keros Therapeutics include Capricor Therapeutics, Audentes Therapeutics and Regulus Therapeutics.
Where is Keros Therapeutics headquarters?
Keros Therapeutics headquarters is located at 99 Hayden Ave suite 120 building e, Lexington.
Where are Keros Therapeutics offices?
Keros Therapeutics has an office in Lexington.
How many offices does Keros Therapeutics have?
Keros Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies